Back to Search
Start Over
Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy.
- Source :
-
Immunotherapy [Immunotherapy] 2021 Dec; Vol. 13 (18), pp. 1501-1519. Date of Electronic Publication: 2021 Oct 21. - Publication Year :
- 2021
-
Abstract
- Background: Immunotherapy changed the landscape of non-small-cell lung cancer (NSCLC). Efforts were made to implement its action. This study aims to describe body composition, nutritional and inflammatory status in NSCLC patients treated by first-line immunotherapy, their correlation, variation and impact. Patients and methods: We retrospectively analyzed 44 consecutive patients who received pembrolizumab treatment. Results: During the therapy, inflammation and visceral fat increased, whereas muscle and subcutaneous fat decreased. Parameters related to inflammation had an interesting prognostic impact. High numbers of white blood cells remained significantly correlated with a high risk of death in multivariate model. Conclusion: For the best treatment choice, a combination of clinical and biological factors will be most likely be necessary. Prospective and larger studies with a multidimensional approach are needed.
- Subjects :
- Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung immunology
Female
Humans
Inflammation etiology
Inflammation immunology
Inflammation therapy
Lung Neoplasms immunology
Male
Middle Aged
Retrospective Studies
Body Composition
Carcinoma, Non-Small-Cell Lung therapy
Immunotherapy adverse effects
Lung Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1750-7448
- Volume :
- 13
- Issue :
- 18
- Database :
- MEDLINE
- Journal :
- Immunotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 34670403
- Full Text :
- https://doi.org/10.2217/imt-2021-0038